Drug Trial Radar · NCT07160179
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Oct 2029
Study completion Oct 2029
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Sep 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD. The purpose of this study is to assess the adverse events and how intravitreal ABBV-6628 moves through the body of adult participants with secondary to age-related macular degeneration ABBV-6628 is an investigational monoclonal antibody fragment being developed for the treatment of geographic atrophy (GA) secondary to (AMD) age-related macular degeneration. Participants in the Stage 1 part will be placed in 1 of 4 groups, called treatment arms. Participants in Stage 2 will be placed into 1 of 2 groups. Each group receives different treatment. Adult participants aged 50 and older years with a diagnosis GA secondary to age-related macular degeneration will be enrolled. Around 66 participants will be enrolled in the study at approximately 27 sites across the US. Participants in Stage 1 will be given ABBV-6628 as an intravitreal injection (injection into the jelly-like tissue that fills the eyeball injection) with dose escalation. Participants in Stage 2 will receive ABBV-6628 or SYFOVRE, an approved treatment for geographic atrophy, administered as per the FDA-approved label. The treatment duration is approximately 22 months and 3 months of follow-up. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Geographic Atrophy
- Age-Related Macular Degeneration
Interventions
ABBV-6628Drug
Intravitreal injection
SYFOVREDrug
Intravitreal injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: Up to approximately 25 months
- Number of Participants with Abnormal Change in Physical ExaminationsTime frame: Up to approximately 25 months
- Number of Participants with Abnormal Change From Baseline in Vital Sign MeasurementsTime frame: Up to approximately 25 months
- Change From Baseline in Electrocardiograms (ECGs)Time frame: Up to approximately 25 months
- Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be AssessedTime frame: Up to approximately 25 months
- Change from baseline in Best Corrected Visual Acuity (BCVA)Time frame: Up to approximately 25 months
- Change in Slit lamp biomicroscopy assessmentTime frame: Up to approximately 25 months
- Change in Intraocular pressure (IOP)Time frame: Up to approximately 25 months
- Change in Lens examination assessmentTime frame: Up to approximately 25 months
- Change in Ophthalmoscopy assessmentTime frame: Up to approximately 25 months
- Change in fundus autofluorescence (FAF) imaging assessed by InvestigatorTime frame: Up to approximately 25 months
- Change in Retinal evaluationTime frame: Up to approximately 25 months
- Change in spectral domain optical coherence tomography (SD-OCT)Time frame: Up to approximately 25 months
- Change in Fluorescein angiography (FA) assessed by Investigator.Time frame: Up to approximately 25 months
- Change in choroidal neovascularization (CNV) assessed by Investigator.Time frame: Up to approximately 25 months
- Percentage of Participants with Clinically Significant Post-treatment Administration Assessment (study eye only) Findings as Assessed by the InvestigatorTime frame: Up to approximately 25 months
- Maximum Serum Concentration (Cmax) of ABBV-6628Time frame: Up to approximately 25 months
- Time to Cmax (Tmax) of ABBV-6628Time frame: Up to approximately 25 months
- Area Under the Concentration-Time Curve From zero to the last measurable Timepoint (AUC0-Tlast) of ABBV-6628Time frame: Up to approximately 25 months
- Stage 2-Trough serum concentration immediately before next dose (Ctrough) of ABBV-6628Time frame: Up to approximately 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Retina Partners Midwest, P.C. /ID# 262172
Carmel, Indiana · Recruiting
Sierra Eye Associates /ID# 262142
Reno, Nevada · Recruiting
Retina Research Institute of Texas /ID# 262141
Abilene, Texas · Recruiting
Retina Foundation of the Southwest /ID# 262479
Dallas, Texas · Recruiting
Retina Consultants - The Woodlands /ID# 262138
The Woodlands, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.